SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Phytovista Laboratories positioned to support CBD industry with testing

    By
    Home / Phytovista Laboratories positioned to support CBD industry with testing

    Estimated reading time: 2 minutes

    Phytovista Laboratories has been given an extension to its ISO 17025 UKAS accreditation.

    Goodbody Health Group has announced its subsidiary Phytovista Laboratories has been given an extension to its accreditation with a test to meet Government Chemist and the Advisory Council on the Misuse of Drugs (ACMD) Guidance.

    The ISO 17025 UKAS accreditation shows that a lab has adequate quality management systems and is able to provide reliable testing and calibration results.  

    Read more: ACMD releases new advice on THC levels in consumer CBD products

    Executive chairman, Geremy Thomas, stated: “This is another example to show how we as a group not only lead the way in supplying the best quality products but also continue to support the whole CBD industry to put quality and compliance first.”

    The Government Chemist highlighted the need for advanced testing for CBD products in its work with the ACMD for the recently published CBD consumer advice. The advice is enabling the UK to lead the way in creating a fully regulated Novel Food consumer CBD market, facilitating consumer choice and confidence.

    Advanced testing methodology is desirable to give the required sensitivity and selectivity to reliably detect traces of residues of controlled cannabinoids in consumer CBD products.

    Read more: Industry responds to new ACMD CBD product advice

    Phytovista Laboratories is one of a very small number accredited for this type of testing.

    Goodbody Health Group stated that PhytoVista laboratories is now ideally positioned to help CBD companies achieve compliance by providing data in accordance with the ACMD guidance on acceptable levels of controlled cannabinoids in consumer products.

    [activecampaign form=31]

    Stephanie Price

    Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine ‘Game Theory’ focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on “Medical Cannabis Explained”.

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free